ClinicalTrials.gov record
Terminated Phase 1Phase 2 Interventional

EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC

ClinicalTrials.gov ID: NCT05075577

Public ClinicalTrials.gov record NCT05075577. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 12:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer

Study identification

NCT ID
NCT05075577
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
ESSA Pharmaceuticals
Industry
Enrollment
77 participants

Conditions and interventions

Interventions

  • EPI-7386 with Enzalutamide Drug
  • Enzalutamide Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 20, 2021
Primary completion
Oct 30, 2024
Completion
Jan 13, 2025
Last update posted
Feb 27, 2025

2021 – 2025

United States locations

U.S. sites
13
U.S. states
9
U.S. cities
11
Facility City State ZIP Site status
Arizona Urology Tucson Arizona 85741
Hematology Oncology Associates of the Treasure Coast Port Saint Lucie Florida 34952
Moffitt Cancer Center Tampa Florida 33612
Chesapeake Urology Associates Baltimore Maryland 21204
Johns Hopkins University Baltimore Maryland 21231
Washington University Siteman Cancer Center St Louis Missouri 63110
Urology Cancer Center Omaha Nebraska 68130
Great Lakes Cancer Center Buffalo New York 14203
Roswell Park Comprehensive Cancer Center Buffalo New York 14203
Memorial Sloan Kettering Cancer Center New York New York 10065
OHSU Knight Cancer Instititue Portland Oregon 97239
Carolina Urologic Research Center Myrtle Beach South Carolina 29572
University of Wisconsin Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05075577, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 27, 2025 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05075577 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →